Should you build or buy Pharma Safety Literature Monitoring & Surveillance?

Pharma Safety Literature Monitoring & Surveillance software automates the systematic screening of published medical literature — journals, case reports, and safety databases — to identify individual case safety reports (ICSRs) that manufacturers are required to submit to regulators under applicable safety-reporting requirements. It handles search execution against licensed databases like Embase and MEDLINE, relevance triage, MedDRA coding, deduplication, and integration with downstream safety case workflows.

Copy reviewed 2026-09-19 · Research revision 2026-09-06

Buy the pipeline, and watch the triage layer. AstraZeneca's patient-safety and AI teams built a deep-learning literature-surveillance triage model, validated it prospectively against their own human reviewers, and qualified it for products where they could show non-inferiority. That is the real proof point in this category, and it is worth taking seriously - the screening labour is where the money goes. But it is one reference. Novartis has published research on the same problem without deploying it, Pfizer's disclosed AI work is case intake rather than literature, and nothing surfaced for Roche. Meanwhile the vendors handle the parts nobody wants to rebuild: Embase and MEDLINE ingestion, deduplication, MedDRA coding, and the routed handoff into the safety database with an audit trail behind it. Buy that, and if your volume justifies it, put your own model in front of it the way AstraZeneca did.

Build it, buy it, or bridge?

⚒ Build it
✓ Buy it
➔ Bridge
Cost shape
Estimate implementation, retained services, integration, validation, and ongoing operations for the defined scope.
Bundled cost covers database access, workflow, and regulatory reporting in one line
Own triage model on top of vendor-managed database and submission layer
Time to value
Depends on the defined scope, data readiness, integrations, and production acceptance tests.
Weeks to onboard; vendor maintains compliance posture ongoing
Faster start via vendor; extend triage model incrementally as capacity allows
Differentiation captured
Can tune recall/precision thresholds to your drug portfolio and risk tolerance
Standardized methodology aligned with industry SOPs and regulator expectations
Vendor handles regulatory scaffold; custom triage logic layered where it matters
AI feasibility today
One validated internal pipeline, research publications, and adjacent intake work cannot support a claim of multiple full production literature-monitoring replacements.
Vendors have integrated NLP screening tools; quality varies and retraining is opaque
Build a bounded literature-screening component with validated review; retain services for source coverage, case handling, traceability, validation, and maintained safety operations.
Who it fits
Teams with a defined need for a bounded literature-screening component with validated review and capacity to operate it.
Smaller biotechs or MAHs without the capacity to maintain NLP models continuously
Mid-size companies that want triage customization but rely on vendor compliance scaffolding

When building makes sense

Consider an internal build for a bounded literature-screening component with validated review. One validated internal pipeline, research publications, and adjacent intake work cannot support a claim of multiple full production literature-monitoring replacements.

When buying makes sense

Buying earns its keep when you need source coverage, case handling, traceability, validation, and maintained safety operations. Compare the vendor’s coverage with the staff, integrations, and controls an internal option would need. Custom extensions can remain useful without replacing the core.

The desk read

Consider an internal build for a bounded literature-screening component with validated review. One validated internal pipeline, research publications, and adjacent intake work cannot support a claim of multiple full production literature-monitoring replacements.

Buying earns its keep when you need source coverage, case handling, traceability, validation, and maintained safety operations. Compare the vendor’s coverage with the staff, integrations, and controls an internal option would need. Custom extensions can remain useful without replacing the core.

Representative vendors ProQuoteMedical / DistillerSR (literature review)ArisGlobal LifeSphere LiteratureClarivate (Embase-adjacent / ProQuest)IQVIA Literature Monitoring + 1 more, listed in the full index

Vendors in Pharma Safety Literature Monitoring & Surveillance

Each file covers what the product is, its funding history, and when the index last verified it alive.

Frequently asked

What is Pharma Safety Literature Monitoring & Surveillance software?

Pharma Safety Literature Monitoring & Surveillance software automates the systematic screening of published medical literature — journals, case reports, and safety databases — to identify individual case safety reports (ICSRs) that manufacturers are required to submit to regulators under applicable safety-reporting requirements. It handles search execution against licensed databases like Embase and MEDLINE, relevance triage, MedDRA coding, deduplication, and integration with downstream safety case workflows.

When does building Pharma Safety Literature Monitoring & Surveillance make sense?

Consider an internal build for a bounded literature-screening component with validated review. One validated internal pipeline, research publications, and adjacent intake work cannot support a claim of multiple full production literature-monitoring replacements.

When does buying Pharma Safety Literature Monitoring & Surveillance make sense?

Buying earns its keep when you need source coverage, case handling, traceability, validation, and maintained safety operations. Compare the vendor’s coverage with the staff, integrations, and controls an internal option would need. Custom extensions can remain useful without replacing the core.

What are the main Pharma Safety Literature Monitoring & Surveillance vendors?

Representative vendors include ProQuoteMedical / DistillerSR (literature review), ArisGlobal LifeSphere Literature, Clarivate (Embase-adjacent / ProQuest), IQVIA Literature Monitoring. B4 Pro includes the category score and the full vendor list.

Is NLP-based literature triage mature enough to rely on in production?

NLP can assist relevance screening within a validated pipeline. The latest research found a narrower production record than the earlier claim of widespread automation. Measure recall, false negatives, and reviewer workload on the actual sources and scope before relying on it.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.